Dupixent Companies: Sanofi, Regeneron Used for: Atopic dermatitis, asthma, chronic rhinosinitus with nasal polyps. 2019 sales: $2.32 billion
Sanofi and Regeneron's long-standing antibody partnership saw some big changes early this year when the pair agreed to rework their deal moving ahead. But one thing won't change: a joint commercial agreement for immunology med Dupixent, which both drugmakers see as a cash cow on the near horizon.
Dupixent could add $1.08 billion to its 2019 sales of $2.32 billion, according to EvaluatePharma. That would bring the blockbuster drug's sales this year up to $3.4 billion.
Sporting a label update after an FDA approval to treat chronic rhinosinitus with nasal polyps, Dupixent is well set to grow its sales in the coming year in a lucrative—and increasingly competitive—eczema market.